Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD2 | P13995 | 4/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 4/20 | 0.42 |
| ▸ | MTOR | P42345 | 3/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13249858 | 0.93 | PRLHR (0.45) | MTHFD2GRM5P2RX7 | |
| SCHEMBL14047859 | 0.93 | MTHFD2 (0.45) | MTHFD2MAOBGRM5MTORP2RX7 | |
| SCHEMBL13249859 | 0.91 | USP2 (0.49) | MTHFD2GRM5CDK4CCND1DRD4 | |
| SCHEMBL13249874 | 0.91 | MTHFD2 (0.43) | MTHFD2MAOBGRM5MTORP2RX7 | |
| SCHEMBL13249851 | 0.90 | GRM5 (0.44) | MTHFD2GRM5 | |
| SCHEMBL13250445 | 0.90 | P2RX7 (0.45) | MTHFD2P2RX7 | |
| SCHEMBL13249840 | 0.89 | MTHFD2 (0.39) | MTHFD2MAOBGRM5MTORP2RX7 | |
| SCHEMBL13249850 | 0.89 | MTHFD2 (0.39) | MTHFD2MAOBGRM5MTORP2RX7 | |
| SCHEMBL13249829 | 0.89 | KMT2A (0.44) | GRM5P2RX7 | |
| SCHEMBL13249864 | 0.89 | GRM5 (0.49) | GRM5CDK4CCND1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR65 | MTHFD2 1349/4885MAOB 1740/4885GRM5 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.